Baker Botts Defeats Takeda's DQ Bid In Heartburn Drug Fight

Law360 (January 14, 2019, 8:28 PM EST) -- Baker Botts LLP can continue representing Zydus Pharmaceuticals as it pursues antitrust claims against Takeda over a heartburn medication, despite the law firm's prior representation of Takeda's ally in patent litigation over the same drug, a New Jersey federal judge said in a ruling made public Friday.

The firm's representation of French drugmaker Ethypharm SA in patent litigation it launched along with Takeda Pharmaceutical Co. Ltd. in New Jersey and Delaware over Takeda's Prevacid SoluTab didn't amount to an attorney-client relationship with Takeda, according to a redacted version of the decision U.S. Magistrate Judge Tonianne A. Bongiovanni rendered Dec. 18....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!